Novartis Pharma Gets EU Approval For Menveo
Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y,
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Novelos said that adding NOV-002 to paclitaxel and carboplatin chemotherapy was not statistically or meaningfully different in terms of efficacy-related endpoints or recovery from chemotherapy toxicity versus chemotherapy
Emisphere’s drug delivery platform, known as the Eligen Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological
The BD Protect system, designed by CDC-trained epidemiologists, addresses multiple issues confronting healthcare administrators and public health officers, including the transmission of multidrug-resistant organisms in healthcare settings and